Skip to main content
SpringerLink
Log in

Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

We evaluated the effect of parathyroid hormone (PTH) on Wnt10b production by immune system cells in humans. We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T cells through increased production of Wnt10b. Chronic increase in PTH as in primary hyperparathyroidism does not increase Wnt10b expression.

Introduction

The aim of this study is to assess the effect of PTH on Wnt10b production by immune system cells in humans. We assessed both the effect of intermittent PTH administration (iPTH) and of chronic PTH hypersecretion in primary hyperparathyroidism (PHP).

Methods

Eighty-two women affected by post-menopausal osteoporosis were randomly assigned to treatment with calcium and vitamin D alone (22) or plus 1-84 PTH (42), or intravenous ibandronate (18). Wnt10b production by unfractioned blood nucleated cells and by T, B cells and monocytes was assessed by real-time RT-PCR and ELISA at baseline, 3, 6, 12 and 18 months of treatment. The effect of chronic elevation of PTH was evaluated in 20 patients affected by PHP at diagnosis and after surgical removal of parathyroid adenoma.

WNT10b from both osteoporotic and PHP patients was compared to healthy subjects matched for age and sex.

Results

iPTH increases Wnt10b production by T cells, whereas PHP does not. After surgical restoration of normal parathyroid function, WNT10b decreases, although it is still comparable with healthy subjects’ level. Thus, chronic elevation of PTH does not significantly increase WNT10b production as respect to control.

Conclusions

This is the first work showing the effect of both intermittent and chronic PTH increase on Wnt10b production by immune system cells. We suggest that, in humans, T cells amplified the anabolic effect of PTH on bone, by increasing Wnt10b production, which stimulates osteoblast activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP (2011) Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Investig 34:801–810. doi:10.3275/7925

    CAS  Google Scholar 

  2. Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180

    Article  CAS  PubMed  Google Scholar 

  3. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  4. Greenspan SL, Bone HG, Ettinger MP et al (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339

    Article  PubMed  Google Scholar 

  5. Thomson M, McCarroll J, Bond J, Gordon-Thomson CD, Williams E, Moore GP (2003) Parathyroid hormone-related peptide modulates signal pathways in skin and hair follicle cells. Exp Dermatol 12:389–395

    Article  CAS  PubMed  Google Scholar 

  6. Gardella TJ, Vilardaga JP (2015) International union of basic and clinical pharmacology. XCIII. The parathyroid hormone receptors-family B G protein-coupled receptors. Pharmacol Rev 67:310–337. doi:10.1124/pr.114.009464

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Fiaschi-Taesch N, Sicari BM, Ubriani K, Bigatel T, Takane KK, Cozar-Castellano I, Bisello A, Law B, Stewart AF (2006) Cellular mechanism through which parathyroid hormone-related protein induces proliferation in arterial smooth muscle cells: definition of an arterial smooth muscle PTHrP/p27kip1 pathway. Circ Res 99:933–942

    Article  CAS  PubMed  Google Scholar 

  8. Faucheux C, Horton MA, Price JS (2002) Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. J Bone Miner Res 17:455–464

    Article  CAS  PubMed  Google Scholar 

  9. Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, Dedic C, Maeda A, Lotinun S, Baron R, Pajevic PD (2013) Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem 288:20122–20134. doi:10.1074/jbc.M112.441360

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957–1967

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M (2012) Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res 27:360–373. doi:10.1002/jbmr.1492

    Article  CAS  PubMed  Google Scholar 

  12. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, Loots GG, Yellowley CE (2010) Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem 110:457–467. doi:10.1002/jcb.22559

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, Lane NE, Harland RM, Loots GG (2012) Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A 109:14092–14097. doi:10.1073/pnas.1207188109

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056–5062. doi:10.1210/jc.2010-072

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Piemonte S, Romagnoli E, Bratengeier C, Woloszczuk W, Tancredi A, Pepe J, Cipriani C, Minisola S (2012) Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Investig 35:866–868. doi:10.3275/8522

    CAS  Google Scholar 

  16. Manolagas SC (2014) Wnt signaling and osteoporosis. Maturitas 78:233–237. doi:10.1016/j.maturitas.2014.04.013

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Bedi B, Li JY, Tawfeek H, Baek KH, Adams J, Vangara SS, Chang MK, Kneissel M, Weitzmann MN, Pacifici R (2012) Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci U S A 109:E725–E733. doi:10.1073/pnas.1120735109

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, Gilbert L, Nanes MS, Zayzafoon M, Guldberg R, Lamar DL, Singer MA, Lane TF, Kronenberg HM, Weitzmann MN, Pacifici R (2009) T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10:229–240. doi:10.1016/j.cmet.2009.07.010

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Li JY, Walker LD, Tyagi AM, Adams J, Weitzmann MN, Pacifici R (2014) The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res 29:43–54. doi:10.1002/jbmr.2044

    Article  PubMed Central  PubMed  Google Scholar 

  20. Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, Gatti D (2013) Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 92:324–329. doi:10.1007/s00223-012-9665-7

    Article  CAS  PubMed  Google Scholar 

  21. Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH (2012) Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int 23:1789–1797. doi:10.1007/s00198-011-1806-8

    Article  CAS  PubMed  Google Scholar 

  22. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka R (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583

    Article  CAS  PubMed  Google Scholar 

  23. Parisien M, Mellish RW, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster DW (1992) Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 7:913–919

    Article  CAS  PubMed  Google Scholar 

  24. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP, Dempster DW (1990) The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 70:930–938

    Article  CAS  PubMed  Google Scholar 

  25. Parisien M, Cosman F, Mellish RW et al (1995) Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 10:1393–1399

    Article  CAS  PubMed  Google Scholar 

  26. Uchiyama T, Tanizawa T, Ito A, Endo N, Takahashi HE (1999) Microstructure of the trabecula and cortex of iliac bone in primary hyperparathyroidism patients determined using histomorphometry and node-strut analysis. J Bone Miner Metab 17:283–288

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by an unconditioned grant from Nycomed SpA (ISAG02AP13) which also provides the PTH 1-84 and calcium and vitamin D supplements. IR was supported by a grant from Italian Ministry of Health: Ricerca Sanitaria Finalizzata e Giovani Ricercatori 2009 (GR 2009-1584485). We are grateful to Prof. G. Gasparri (University of Turin, Italy) for recruiting PHP patients.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Gerontology Section, Department of Medical Science, University of Torino, Corso Bramante 88/90, 10126, Torino, Italy

    P. D’Amelio, F. Sassi, I. Buondonno, G. Fornelli, E. Spertino, M. Marchetti & G. C. Isaia

  2. CeRMS, Città della Salute e della Scienza University Hospital of Torino-Italy, Torino, Italy

    L. D’Amico & I. Roato

  3. Clinical Biochemistry Laboratory, Città della Salute e della Scienza University Hospital of Torino-Italy, Torino, Italy

    M. Lucchiari

Authors
  1. P. D’Amelio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Sassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Buondonno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Fornelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Spertino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. D’Amico
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Lucchiari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. Roato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. C. Isaia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. D’Amelio.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Amelio, P., Sassi, F., Buondonno, I. et al. Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients. Osteoporos Int 26, 2785–2791 (2015). https://doi.org/10.1007/s00198-015-3189-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-015-3189-8

Keywords

Search

Navigation